RET-话题@MedSci - williamhill asia

#RET#

170篇内容 | 2598人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2198693, encodeId=f712219869367, content=<a href='/topic/show?id=32af9938ec6' target=_blank style='color:#2F92EE;'>#非小细胞肺癌#</a> <a href='/topic/show?id=d67212e68d7' target=_blank style='color:#2F92EE;'>#NGS#</a> <a href='/topic/show?id=4684153e41f' target=_blank style='color:#2F92EE;'>#RET#</a>, objectTitle=非小细胞肺癌RET融合检测平台如何选？基于RNA的NGS优于FISH和RT-PCR, objectType=article, longId=821724, objectId=0069821e24a6, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/doctor-signing-contract-V6EFLDM.jpg, objectUrl=/article/show_article.do?id=0069821e24a6, replyNumber=0, likeNumber=52, createdTime=2024-04-15, rootId=0, userName=williamhill asia 管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=陕西省, moduleDTOList=[ModuleDTO(moduleId=0069821e24a6, moduleTitle=非小细胞肺癌RET融合检测平台如何选？基于RNA的NGS优于FISH和RT-PCR, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=0069821e24a6)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=1913964, encodeId=528d1913964ea, content=<a href='/topic/show?id=4684153e41f' target=_blank style='color:#2F92EE;'>#RET#</a>, objectTitle=AJG: 巴雷特(Barrett's)食管治疗后的监测最有利于预防重度不典型增生或黏膜内癌的发生, objectType=article, longId=731126, objectId=e399e3112679, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e399e3112679, replyNumber=0, likeNumber=68, createdTime=2022-08-16, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e399e3112679, moduleTitle=AJG: 巴雷特(Barrett's)食管治疗后的监测最有利于预防重度不典型增生或黏膜内癌的发生, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=e399e3112679)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1913962, encodeId=56421913962b5, content=<a href='/topic/show?id=4684153e41f' target=_blank style='color:#2F92EE;'>#RET#</a>, objectTitle=Thorac Cancer：真实世界中晚期NSCLC患者伴有KRAS、MET、FGFR、RET、BRAF和HER2改变时一线使用免疫检查点抑制剂(ICIs)的疗效, objectType=article, longId=727690, objectId=5f10e2769003, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5f10e2769003, replyNumber=0, likeNumber=63, createdTime=2023-03-17, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5f10e2769003, moduleTitle=Thorac Cancer：真实世界中晚期NSCLC患者伴有KRAS、MET、FGFR、RET、BRAF和HER2改变时一线使用免疫检查点抑制剂(ICIs)的疗效, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=5f10e2769003)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1913965, encodeId=464b19139657f, content=<a href='/topic/show?id=4684153e41f' target=_blank style='color:#2F92EE;'>#RET#</a>, objectTitle=Eur Arch Otorhinolaryngol：血清生物标志物pretin与感音神经性听力损失有何关系？, objectType=article, longId=736961, objectId=3831e36961f8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3831e36961f8, replyNumber=0, likeNumber=59, createdTime=2023-05-18, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3831e36961f8, moduleTitle=Eur Arch Otorhinolaryngol：血清生物标志物pretin与感音神经性听力损失有何关系？, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=3831e36961f8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1913961, encodeId=45fd1913961a2, content=<a href='/topic/show?id=4684153e41f' target=_blank style='color:#2F92EE;'>#RET#</a>, objectTitle=ViiV Healthcare宣布美国FDA已核准用于预防HIV的首个长效针剂Apretude（卡博特韦缓释注射混悬液）, objectType=article, longId=292640, objectId=6d43292640c9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6d43292640c9, replyNumber=0, likeNumber=62, createdTime=2022-03-01, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6d43292640c9, moduleTitle=ViiV Healthcare宣布美国FDA已核准用于预防HIV的首个长效针剂Apretude（卡博特韦缓释注射混悬液）, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=6d43292640c9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1913963, encodeId=e0ae19139636e, content=<a href='/topic/show?id=4684153e41f' target=_blank style='color:#2F92EE;'>#RET#</a>, objectTitle=Barrett食管（巴雷特）如何诊疗，这篇文章讲清楚了！, objectType=article, longId=730788, objectId=6945e30788e5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6945e30788e5, replyNumber=0, likeNumber=82, createdTime=2022-11-19, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6945e30788e5, moduleTitle=Barrett食管（巴雷特）如何诊疗，这篇文章讲清楚了！, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=6945e30788e5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1913958, encodeId=282f19139580c, content=<a href='/topic/show?id=4684153e41f' target=_blank style='color:#2F92EE;'>#RET#</a>, objectTitle=Resensitization of cisplatin resistance ovarian cancer cells to cisplatin through pretreatment with low‐dose fraction radiation, objectType=article, longId=221060, objectId=69b22210602c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=69b22210602c, replyNumber=0, likeNumber=60, createdTime=2022-06-15, rootId=0, userName=ysjykql, userId=96d4340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=69b22210602c, moduleTitle=Resensitization of cisplatin resistance ovarian cancer cells to cisplatin through pretreatment with low‐dose fraction radiation, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=69b22210602c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1913959, encodeId=adf4191395983, content=<a href='/topic/show?id=4684153e41f' target=_blank style='color:#2F92EE;'>#RET#</a>, objectTitle=Barrett食管（巴雷特）如何诊疗，一文囊括！, objectType=article, longId=292220, objectId=402d29222093, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=402d29222093, replyNumber=0, likeNumber=86, createdTime=2022-08-12, rootId=0, userName=ysjykql, userId=96d4340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=402d29222093, moduleTitle=Barrett食管（巴雷特）如何诊疗，一文囊括！, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=402d29222093)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1913954, encodeId=1cb91913954aa, content=<a href='/topic/show?id=4684153e41f' target=_blank style='color:#2F92EE;'>#RET#</a>, objectTitle=Clin Cancer Res：Selpercatinib在已发生脑转移的RET融合阳性NSCLC患者中的疗效(LIBRETTO-001研究), objectType=article, longId=215428, objectId=756f215428da, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=756f215428da, replyNumber=0, likeNumber=57, createdTime=2021-08-09, rootId=0, userName=仁医06, userId=55683, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=756f215428da, moduleTitle=Clin Cancer Res：Selpercatinib在已发生脑转移的RET融合阳性NSCLC患者中的疗效(LIBRETTO-001研究), moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=756f215428da)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1913956, encodeId=2d06191395643, content=<a href='/topic/show?id=4684153e41f' target=_blank style='color:#2F92EE;'>#RET#</a>, objectTitle=ANANDA Scientific与加州大学洛杉矶分校David Geffen医学院宣布开展采用Liquid StructureTM大麻二酚(CBD)治疗阿片类用药障碍(OUD)的临床试验, objectType=article, longId=217999, objectId=3cbb21e9990e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3cbb21e9990e, replyNumber=0, likeNumber=73, createdTime=2022-05-07, rootId=0, userName=ysjykql, userId=96d4340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3cbb21e9990e, moduleTitle=ANANDA Scientific与加州大学洛杉矶分校David Geffen医学院宣布开展采用Liquid StructureTM大麻二酚(CBD)治疗阿片类用药障碍(OUD)的临床试验, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=3cbb21e9990e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1913953, encodeId=d089191395359, content=<a href='/topic/show?id=4684153e41f' target=_blank style='color:#2F92EE;'>#RET#</a>, objectTitle=RET突变有没有很好疗效的药物？, objectType=article, longId=215079, objectId=3dc72150e931, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3dc72150e931, replyNumber=0, likeNumber=79, createdTime=2021-10-05, rootId=0, userName=ysjykql, userId=96d4340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3dc72150e931, moduleTitle=RET突变有没有很好疗效的药物？, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=3dc72150e931)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1913949, encodeId=0a6e19139497e, content=<a href='/topic/show?id=4684153e41f' target=_blank style='color:#2F92EE;'>#RET#</a>, objectTitle=Translational Psychiatry：Tourette综合征的CSTC回路脑区灰质存在异常变化, objectType=article, longId=211473, objectId=3e4c2114e306, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3e4c2114e306, replyNumber=0, likeNumber=64, createdTime=2021-12-16, rootId=0, userName=ysjykql, userId=96d4340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3e4c2114e306, moduleTitle=Translational Psychiatry：Tourette综合征的CSTC回路脑区灰质存在异常变化, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=3e4c2114e306)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1913957, encodeId=9288191395e87, content=<a href='/topic/show?id=4684153e41f' target=_blank style='color:#2F92EE;'>#RET#</a>, objectTitle=Lancet rheumatology:类风湿性关节炎稳定缓解期患者的治疗逐渐减量和停止(RETRO)：一项多中心、随机、对照、开放标签3期试验, objectType=article, longId=219099, objectId=6d25219099a0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6d25219099a0, replyNumber=0, likeNumber=80, createdTime=2022-06-23, rootId=0, userName=ysjykql, userId=96d4340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6d25219099a0, moduleTitle=Lancet rheumatology:类风湿性关节炎稳定缓解期患者的治疗逐渐减量和停止(RETRO)：一项多中心、随机、对照、开放标签3期试验, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=6d25219099a0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1913960, encodeId=07391913960c4, content=<a href='/topic/show?id=4684153e41f' target=_blank style='color:#2F92EE;'>#RET#</a>, objectTitle=CHMP对 Kineret (anakinra) 治疗COVID-19持积极意见, objectType=article, longId=292250, objectId=43db292250ee, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=43db292250ee, replyNumber=0, likeNumber=70, createdTime=2022-08-03, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=43db292250ee, moduleTitle=CHMP对 Kineret (anakinra) 治疗COVID-19持积极意见, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=43db292250ee)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1913950, encodeId=de1a1913950c4, content=<a href='/topic/show?id=4684153e41f' target=_blank style='color:#2F92EE;'>#RET#</a>, objectTitle=Lancet子刊 | RET抑制剂--Pralsetinib治疗甲状腺癌，实现生存重磅突破！, objectType=article, longId=212611, objectId=74632126115d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=74632126115d, replyNumber=0, likeNumber=59, createdTime=2021-10-30, rootId=0, userName=ysjykql, userId=96d4340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=74632126115d, moduleTitle=Lancet子刊 | RET抑制剂--Pralsetinib治疗甲状腺癌，实现生存重磅突破！, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=74632126115d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1913952, encodeId=dd6a191395277, content=<a href='/topic/show?id=4684153e41f' target=_blank style='color:#2F92EE;'>#RET#</a>, objectTitle=Lancet Oncol：普拉替尼有望用于治疗RET融合阳性的非小细胞肺癌（ARROW试验）, objectType=article, longId=213322, objectId=b9b021332249, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b9b021332249, replyNumber=0, likeNumber=72, createdTime=2021-10-07, rootId=0, userName=ysjykql, userId=96d4340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b9b021332249, moduleTitle=Lancet Oncol：普拉替尼有望用于治疗RET融合阳性的非小细胞肺癌（ARROW试验）, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=b9b021332249)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1913944, encodeId=0e1a191394453, content=<a href='/topic/show?id=4684153e41f' target=_blank style='color:#2F92EE;'>#RET#</a>, objectTitle=FDA批准RET抑制剂pralsetinib新适应症！治疗甲状腺髓样癌, objectType=article, longId=204111, objectId=394820411175, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=394820411175, replyNumber=0, likeNumber=108, createdTime=2021-05-10, rootId=0, userName=ysjykql, userId=96d4340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=394820411175, moduleTitle=FDA批准RET抑制剂pralsetinib新适应症！治疗甲状腺髓样癌, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=394820411175)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1913951, encodeId=cca1191395127, content=<a href='/topic/show?id=4684153e41f' target=_blank style='color:#2F92EE;'>#RET#</a>, objectTitle=Lancet oncol：Pralsetinib有望用于治疗RET融合阳性的NSCLC, objectType=article, longId=212697, objectId=084e21269e30, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=084e21269e30, replyNumber=0, likeNumber=59, createdTime=2021-08-06, rootId=0, userName=ysjykql, userId=96d4340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=084e21269e30, moduleTitle=Lancet oncol：Pralsetinib有望用于治疗RET融合阳性的NSCLC, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=084e21269e30)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1913955, encodeId=a0e41913955bf, content=<a href='/topic/show?id=4684153e41f' target=_blank style='color:#2F92EE;'>#RET#</a>, objectTitle=Gastroenterology：Barrett食管患者多大年龄时可停止进行内镜监测？, objectType=article, longId=215860, objectId=f45b215860fd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f45b215860fd, replyNumber=0, likeNumber=87, createdTime=2021-12-17, rootId=0, userName=ysjykql, userId=96d4340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f45b215860fd, moduleTitle=Gastroenterology：Barrett食管患者多大年龄时可停止进行内镜监测？, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=f45b215860fd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1913945, encodeId=c6e5191394564, content=<a href='/topic/show?id=4684153e41f' target=_blank style='color:#2F92EE;'>#RET#</a>, objectTitle=Ann Surg：AS-DD术式治疗长段Barrett食管的远期（18年）预后！, objectType=article, longId=206246, objectId=ca222062466c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ca222062466c, replyNumber=0, likeNumber=75, createdTime=2021-07-24, rootId=0, userName=ysjykql, userId=96d4340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ca222062466c, moduleTitle=Ann Surg：AS-DD术式治疗长段Barrett食管的远期（18年）预后！, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=ca222062466c)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] williamhill asia 话题小助手

RET

2020-05-29

williamhill asia 管理员 (审核中...)

前往app查看评论内容

#非小细胞肺癌# #NGS# #RET#

非小细胞肺癌RET融合检测平台如何选？基于RNA的NGS优于FISH和RT-PCR

2024-04-15发表于陕西省

智者为医08 (审核中...)

前往app查看评论内容

#RET#

AJG: 巴雷特(Barrett's)食管治疗后的监测最有利于预防重度不典型增生或黏膜内癌的发生

2022-08-16

智者为医08 (审核中...)

前往app查看评论内容

#RET#

Thorac Cancer：真实世界中晚期NSCLC患者伴有KRAS、MET、FGFR、RET、BRAF和HER2改变时一线使用免疫检查点抑制剂(ICIs)的疗效

2023-03-17

智者为医08 (审核中...)

前往app查看评论内容

#RET#

Eur Arch Otorhinolaryngol：血清生物标志物pretin与感音神经性听力损失有何关系？

2023-05-18

智者为医08 (审核中...)

前往app查看评论内容

#RET#

ViiV Healthcare宣布美国FDA已核准用于预防HIV的首个长效针剂Apretude（卡博特韦缓释注射混悬液）

2022-03-01

智者为医08 (审核中...)

前往app查看评论内容

#RET#

Barrett食管（巴雷特）如何诊疗，这篇文章讲清楚了！

2022-11-19

ysjykql (审核中...)

前往app查看评论内容

#RET#

Resensitization of cisplatin resistance ovarian cancer cells to cisplatin through pretreatment with low‐dose fraction radiation

2022-06-15

ysjykql (审核中...)

前往app查看评论内容

#RET#

Barrett食管（巴雷特）如何诊疗，一文囊括！

2022-08-12

仁医06 (审核中...)

前往app查看评论内容

#RET#

Clin Cancer Res：Selpercatinib在已发生脑转移的RET融合阳性NSCLC患者中的疗效(LIBRETTO-001研究)

2021-08-09

ysjykql (审核中...)

前往app查看评论内容

#RET#

ANANDA Scientific与加州大学洛杉矶分校David Geffen医学院宣布开展采用Liquid StructureTM大麻二酚(CBD)治疗阿片类用药障碍(OUD)的临床试验

2022-05-07

ysjykql (审核中...)

前往app查看评论内容

#RET#

RET突变有没有很好疗效的药物？

2021-10-05

ysjykql (审核中...)

前往app查看评论内容

#RET#

Translational Psychiatry：Tourette综合征的CSTC回路脑区灰质存在异常变化

2021-12-16

ysjykql (审核中...)

前往app查看评论内容

#RET#

Lancet rheumatology:类风湿性关节炎稳定缓解期患者的治疗逐渐减量和停止(RETRO)：一项多中心、随机、对照、开放标签3期试验

2022-06-23

智者为医08 (审核中...)

前往app查看评论内容

#RET#

CHMP对 Kineret (anakinra) 治疗COVID-19持积极意见

2022-08-03

ysjykql (审核中...)

前往app查看评论内容

#RET#

Lancet子刊 | RET抑制剂--Pralsetinib治疗甲状腺癌，实现生存重磅突破！

2021-10-30

ysjykql (审核中...)

前往app查看评论内容

#RET#

Lancet Oncol：普拉替尼有望用于治疗RET融合阳性的非小细胞肺癌（ARROW试验）

2021-10-07

ysjykql (审核中...)

前往app查看评论内容

#RET#

FDA批准RET抑制剂pralsetinib新适应症！治疗甲状腺髓样癌

2021-05-10

ysjykql (审核中...)

前往app查看评论内容

#RET#

Lancet oncol：Pralsetinib有望用于治疗RET融合阳性的NSCLC

2021-08-06

ysjykql (审核中...)

前往app查看评论内容

#RET#

Gastroenterology：Barrett食管患者多大年龄时可停止进行内镜监测？

2021-12-17

ysjykql (审核中...)

前往app查看评论内容

#RET#

Ann Surg：AS-DD术式治疗长段Barrett食管的远期（18年）预后！

2021-07-24

科室
- - 订阅+
  - 更多科室
工具
服务